{"id":33445,"date":"2025-09-23T17:03:21","date_gmt":"2025-09-23T11:33:21","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=33445"},"modified":"2025-09-23T17:06:02","modified_gmt":"2025-09-23T11:36:02","slug":"pharma-news-for-merck-incyte-biocon","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-merck-incyte-biocon","title":{"rendered":"Merck Wins FDA Approval for KEYTRUDA QLEX for Subcutaneous Use in Adults With Solid Tumors; Incyte Gains FDA Nod for OPZELURA Cream in Children Aged 2\u201311 With Atopic Dermatitis; Minovia Therapeutics Receives FDA Fast Track Designation for MNV-201 in Myelodysplastic Syndrome; MavriX Bio Secures FDA Fast Track for MVX-220 Gene Therapy in Angelman Syndrome; Biocon Biologics Gets FDA Approval for Denosumab Biosimilars BOSAYA and AUKELSO"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a041dfa7d626\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a041dfa7d626\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-merck-incyte-biocon\/#FDA_Approves_Mercks_KEYTRUDA_QLEX_for_Subcutaneous_Use_Across_Multiple_Solid_Tumors\" >FDA Approves Merck\u2019s KEYTRUDA QLEX for Subcutaneous Use Across Multiple Solid Tumors<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-merck-incyte-biocon\/#Incyte_Secures_FDA_Nod_for_OPZELURA_Cream_in_Children_2%E2%80%9311_With_Atopic_Dermatitis\" >Incyte Secures FDA Nod for OPZELURA Cream in Children (2\u201311) With Atopic Dermatitis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-merck-incyte-biocon\/#Minovia_Therapeutics_Gets_FDA_Fast_Track_for_MNV-201_in_Myelodysplastic_Syndrome\" >Minovia Therapeutics Gets FDA Fast Track for MNV-201 in Myelodysplastic Syndrome<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-merck-incyte-biocon\/#MavriX_Bio_Awarded_FDA_Fast_Track_for_MVX-220_Gene_Therapy_in_Angelman_Syndrome\" >MavriX Bio Awarded FDA Fast Track for MVX-220 Gene Therapy in Angelman Syndrome<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-merck-incyte-biocon\/#Biocon_Biologics_Gains_FDA_Approval_for_Denosumab_Biosimilars_BOSAYA_and_AUKELSO\" >Biocon Biologics Gains FDA Approval for Denosumab Biosimilars BOSAYA and AUKELSO<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-approves-merck-s-keytruda-qlex-for-subcutaneous-use-across-multiple-solid-tumors\"><span class=\"ez-toc-section\" id=\"FDA_Approves_Mercks_KEYTRUDA_QLEX_for_Subcutaneous_Use_Across_Multiple_Solid_Tumors\"><\/span>FDA Approves Merck\u2019s KEYTRUDA QLEX for Subcutaneous Use Across Multiple Solid Tumors<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Merck<\/strong> announced that the FDA has approved <strong>KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph)<\/strong> for subcutaneous administration in adults across most of KEYTRUDA\u2019s approved solid tumor indications. Unlike the intravenous (IV) formulation, KEYTRUDA QLEX can be administered by a healthcare provider in as little as one minute, offering patients a faster and more flexible treatment option.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThis approval is significant for patients and health care providers like me who have been using immunotherapies for years to treat certain cancers. We now have a new option with a broad set of indications that has demonstrated comparability with IV pembrolizumab but in a subcutaneous injection that can be administered in one minute every three weeks or two minutes every six weeks,\u201d said <\/em><strong><em>Dr. J. Thaddeus Beck<\/em><\/strong><em>, oncologist and Medical Director of the Highlands\u2019 Clinical Trials Office.<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The FDA decision was supported by a pivotal trial in <strong>treatment-na\u00efve <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-non-small-cell-lung-cancer-market\"><strong>metastatic non-small cell lung cancer (NSCLC)<\/strong> patients<\/a>, which compared subcutaneous KEYTRUDA QLEX to IV KEYTRUDA. Results showed similar pharmacokinetics, safety, and efficacy outcomes, with overall response rates of 45% versus 42%, respectively, and no notable differences in progression-free or overall survival.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cAt Merck, we are committed to putting patients first, as we work relentlessly to discover new options that may help patients manage their treatment in a way that fits their needs,\u201d said <\/em><strong><em>Dr. Marjorie Green<\/em><\/strong><em>, senior vice president and head of oncology, global clinical development, Merck Research Laboratories. \u201cWe are honored to build on the foundation of KEYTRUDA with KEYTRUDA QLEX, a new injectable immunotherapy option that has similar results to KEYTRUDA and can be administered in as little as one minute.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>Merck expects KEYTRUDA QLEX to be available in the U.S. in late September, providing patients and physicians with a convenient alternative to IV infusions and expanding treatment access across multiple care settings.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-incyte-secures-fda-nod-for-opzelura-cream-in-children-2-11-with-atopic-dermatitis\"><span class=\"ez-toc-section\" id=\"Incyte_Secures_FDA_Nod_for_OPZELURA_Cream_in_Children_2%E2%80%9311_With_Atopic_Dermatitis\"><\/span>Incyte Secures FDA Nod for OPZELURA Cream in Children (2\u201311) With Atopic Dermatitis<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Incyte announced that the FDA has approved <strong>OPZELURA (ruxolitinib) cream 1.5%<\/strong> for the short-term and non-continuous chronic treatment of<strong> <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/atopic-dermatitis-market\"><strong>mild to moderate atopic dermatitis (AD)<\/strong><\/a> in non-immunocompromised children aged two years and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cWith this approval, we are now able to offer younger children with atopic dermatitis and their families a much-needed, steroid-free topical treatment option with the potential to significantly improve the burdensome symptoms they experience every day,\u201d said <\/em><strong><em>Bill Meury, Chief Executive Officer, Incyte<\/em><\/strong><em>.<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The decision was supported by positive results from the <strong>phase III TRuE-AD3 trial<\/strong>, which evaluated ruxolitinib cream in children aged \u22652 to &lt;12 years with AD. The study met its primary endpoint, with significantly more patients achieving Investigator\u2019s Global Assessment-treatment success (IGA-TS) compared to vehicle control, alongside secondary endpoints including EASI75 response at Week 8. The safety profile was consistent with earlier studies, with no new safety signals observed.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cChildren with atopic dermatitis currently have limited treatment options to meet their specific needs,\u201d said <\/em><strong><em>Dr. Peter Lio, Clinical Assistant Professor of Dermatology &amp; Pediatrics at Northwestern University Feinberg School of Medicine<\/em><\/strong><em>. \u201cWith this approval, we now have a new, non-steroidal topical option that expands how we care for kids with this chronic disease.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-minovia-therapeutics-gets-fda-fast-track-for-mnv-201-in-myelodysplastic-syndrome\"><span class=\"ez-toc-section\" id=\"Minovia_Therapeutics_Gets_FDA_Fast_Track_for_MNV-201_in_Myelodysplastic_Syndrome\"><\/span>Minovia Therapeutics Gets FDA Fast Track for MNV-201 in Myelodysplastic Syndrome<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Minovia Therapeutics Ltd., a clinical-stage biotechnology company developing mitochondrial-targeted therapies, announced that the FDA has granted <strong>Fast Track Designation (FTD)<\/strong> to its lead investigational compound, <strong>MNV-201<\/strong>, for the treatment of <a href=\"https:\/\/www.delveinsight.com\/report-store\/myelodysplastic-syndrome-market\"><strong>myelodysplastic syndrome (MDS)<\/strong><\/a>, a serious hematopoietic disease associated with aging.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThe Fast Track Designation in MDS is further validation of the urgency and potential for our science, which targets the mitochondria, a critical multi-functional organelle,\u201d said <\/em><strong><em>Natalie Yivgi-Ohana, Ph.D., Co-founder and CEO of Minovia<\/em><\/strong><em>. \u201cFDA designations such as the FTD help us decrease the potential time to market and provide additional benefits across the FDA process that, we expect, will prove both medically and financially valuable.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>MNV-201 already holds <strong>Fast Track and Rare Pediatric Disease Designations<\/strong> for <strong>Pearson Syndrome<\/strong>, an ultra-rare mitochondrial disorder affecting children, for which Minovia is currently conducting a <strong>phase II clinical trial<\/strong>. The new designation broadens the potential of the therapy across both rare pediatric and age-related diseases.<\/p>\n\n\n\n<p>In parallel, Minovia has entered into a <strong>definitive business combination agreement with Launch One Acquisition Corp. (Nasdaq: LPAA)<\/strong>, a SPAC. Upon closing of the transaction, expected in late 2025, the combined company will operate as Minovia Therapeutics and trade on Nasdaq under a new ticker symbol.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-mavrix-bio-awarded-fda-fast-track-for-mvx-220-gene-therapy-in-angelman-syndrome\"><span class=\"ez-toc-section\" id=\"MavriX_Bio_Awarded_FDA_Fast_Track_for_MVX-220_Gene_Therapy_in_Angelman_Syndrome\"><\/span>MavriX Bio Awarded FDA Fast Track for MVX-220 Gene Therapy in Angelman Syndrome<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>MavriX Bio<\/strong> announced that the FDA has granted <strong>Fast Track designation<\/strong> to <strong>MVX-220<\/strong>, its investigational AAV-based gene therapy for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/angelman-syndrome-market-forecast\">treatment of <strong>Angelman syndrome (AS)<\/strong><\/a>. The designation underscores the urgent need for innovative therapies in this rare neurological disorder.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThe FDA\u2019s decision reflects the urgent need for therapies for individuals living with Angelman syndrome,\u201d said <\/em><strong><em>Allyson Berent, DVM, DACVIM, Chief Development Officer of MavriX Bio<\/em><\/strong><em>. \u201cThis designation highlights the promise MVX-220 holds and enables closer collaboration with the FDA and an accelerated path forward.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>In <strong>May 2025<\/strong>, MavriX received <strong>IND clearance<\/strong> for MVX-220 and is preparing to launch <strong>ASCEND-AS, a phase I\/II first-in-human study<\/strong>. The company aims to evaluate the safety and potential efficacy of the therapy in patients with Angelman syndrome.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cFast Track status gives this program crucial momentum,\u201d said <\/em><strong><em>James M. Wilson, MD, PhD, CEO of GEMMA Biotherapeutics (GEMMABio)<\/em><\/strong><em>, whose team developed MVX-220. \u201cFor the Angelman community, it opens a path toward bringing gene-targeted therapies to patients sooner.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-biocon-biologics-gains-fda-approval-for-denosumab-biosimilars-bosaya-and-aukelso\"><span class=\"ez-toc-section\" id=\"Biocon_Biologics_Gains_FDA_Approval_for_Denosumab_Biosimilars_BOSAYA_and_AUKELSO\"><\/span>Biocon Biologics Gains FDA Approval for Denosumab Biosimilars BOSAYA and AUKELSO<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Biocon Biologics Ltd. (BBL)<\/strong>, a subsidiary of Biocon Ltd., announced that the FDA has approved <strong>BOSAYA (denosumab-kyqq) 60 mg\/mL injection<\/strong> and <strong>AUKELSO (denosumab-kyqq) 120 mg\/1.7 mL injection<\/strong>, biosimilars to <strong>PROLIA<\/strong> and <strong>XGEVA,<\/strong> respectively. Both medicines also received provisional interchangeability designation, a milestone that expands treatment options for <a href=\"https:\/\/www.delveinsight.com\/report-store\/osteoporosis-market\">patients with osteoporosis<\/a> and those undergoing oncology care.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThe FDA\u2019s approval of BOSAYA and AUKELSO is a significant milestone in our mission to expand access to critical biologic therapies,\u201d said <\/em><strong><em>Shreehas Tambe, CEO &amp; Managing Director, Biocon Biologics<\/em><\/strong><em>. \u201cWith BOSAYA\u2122, we are proud to offer a more affordable treatment for osteoporosis, and with AUKELSO\u2122, we are expanding our oncology portfolio, underscoring our commitment to sustainable healthcare systems and better patient outcomes.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>BOSAYA is approved for multiple indications, including <a href=\"https:\/\/www.delveinsight.com\/report-store\/post-menopausal-osteoporosis-market\"><strong>postmenopausal osteoporosis<\/strong><\/a><strong>, glucocorticoid-induced osteoporosis, and bone loss in patients receiving cancer therapies<\/strong>. AUKELSO is indicated for the prevention of skeletal-related events in <a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-myeloma-market\">multiple myeloma<\/a> and solid tumor bone metastases, giant cell tumor of bone, and <a href=\"https:\/\/www.delveinsight.com\/report-store\/hyperkalemia-market\">hypercalcemia<\/a> of malignancy refractory to bisphosphonates. Both biosimilars demonstrated comparable quality, safety, and efficacy to their reference products in clinical evaluations.<\/p>\n\n\n\n<p>According to IQVIA data, denosumab generated nearly $5 billion in U.S. sales in 2024, with PROLIA accounting for $3.3 billion and XGEVA $1.6 billion. With these approvals, Biocon Biologics positions itself as a key player in delivering high-quality, cost-effective biologics to address the growing needs of patients.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>FDA Approves Merck\u2019s KEYTRUDA QLEX for Subcutaneous Use Across Multiple Solid Tumors Merck announced that the FDA has approved KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) for subcutaneous administration in adults across most of KEYTRUDA\u2019s approved solid tumor indications. Unlike the intravenous (IV) formulation, KEYTRUDA QLEX can be administered by a healthcare provider in as little [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":33446,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[18321,2387,17928,7485,7483,7484,7478,7467,7469,17926,704,349,22020,410,2833,16669,21278,21279,21277,18088,420,6733,979,12555,1500,6616,3278,6615,3280,639,5789],"industry":[17225],"therapeutic_areas":[17237,17240,17238,17233,17241,17228],"class_list":["post-33445","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-advanced-multiple-myeloma","tag-angelman-syndrome","tag-angelman-syndrome-current-treatment-landscape","tag-angelman-syndrome-epidemiology","tag-angelman-syndrome-market","tag-angelman-syndrome-pipeline","tag-atopic-dermatitis","tag-atopic-dermatitis-market","tag-atopic-dermatitis-treatment-market","tag-atopic-dermatitis-upcoming-therapies","tag-fda","tag-latest-pharma-news","tag-metastatic-non-small-cell-lung-cancer","tag-multiple-myeloma","tag-multiple-myeloma-drugs-market","tag-multiple-myeloma-market","tag-myelodysplastic-syndrome-market","tag-myelodysplastic-syndrome-pipeline","tag-myelodysplastic-syndrome-treatment","tag-myelodysplastic-syndromes","tag-news","tag-non-small-cell-lung-cancer","tag-non-small-cell-lung-cancer-nsclc","tag-non-small-cell-lung-cancer-market","tag-osteoporosis","tag-osteoporosis-drugs","tag-osteoporosis-market","tag-osteoporosis-therapy-market","tag-osteoporosis-treatment","tag-pharma-news","tag-recent-pharma-news","industry-pharmaceutical","therapeutic_areas-dermatology","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-genetic-disorders","therapeutic_areas-hematological-disorders","therapeutic_areas-musculoskeletal","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | Merck, Incyte, Biocon<\/title>\n<meta name=\"description\" content=\"Merck\u2019s KEYTRUDA QLEX; Incyte\u2019s OPZELURA Cream; Minovia\u2019s MNV-201; MavriX Bio\u2019s MVX-220 Gene Therapy; Biocon Biologics\u2019 BOSAYA and AUKELSO\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-merck-incyte-biocon\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Merck, Incyte, Biocon\" \/>\n<meta property=\"og:description\" content=\"Merck\u2019s KEYTRUDA QLEX; Incyte\u2019s OPZELURA Cream; Minovia\u2019s MNV-201; MavriX Bio\u2019s MVX-220 Gene Therapy; Biocon Biologics\u2019 BOSAYA and AUKELSO\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-merck-incyte-biocon\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-23T11:33:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-23T11:36:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/23165259\/23-09-2025-feature.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Merck, Incyte, Biocon","description":"Merck\u2019s KEYTRUDA QLEX; Incyte\u2019s OPZELURA Cream; Minovia\u2019s MNV-201; MavriX Bio\u2019s MVX-220 Gene Therapy; Biocon Biologics\u2019 BOSAYA and AUKELSO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-merck-incyte-biocon","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Merck, Incyte, Biocon","og_description":"Merck\u2019s KEYTRUDA QLEX; Incyte\u2019s OPZELURA Cream; Minovia\u2019s MNV-201; MavriX Bio\u2019s MVX-220 Gene Therapy; Biocon Biologics\u2019 BOSAYA and AUKELSO","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-merck-incyte-biocon","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-09-23T11:33:21+00:00","article_modified_time":"2025-09-23T11:36:02+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/23165259\/23-09-2025-feature.webp","type":"image\/webp"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-merck-incyte-biocon","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-merck-incyte-biocon","name":"Pharma News | Merck, Incyte, Biocon","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-merck-incyte-biocon#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-merck-incyte-biocon#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/23165259\/23-09-2025-feature.webp","datePublished":"2025-09-23T11:33:21+00:00","dateModified":"2025-09-23T11:36:02+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"Merck\u2019s KEYTRUDA QLEX; Incyte\u2019s OPZELURA Cream; Minovia\u2019s MNV-201; MavriX Bio\u2019s MVX-220 Gene Therapy; Biocon Biologics\u2019 BOSAYA and AUKELSO","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-for-merck-incyte-biocon"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-merck-incyte-biocon#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/23165259\/23-09-2025-feature.webp","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/23165259\/23-09-2025-feature.webp","width":772,"height":482,"caption":"pharma-news-for-merck-incyte-biocon"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/23165259\/23-09-2025-feature-300x187.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Advanced Multiple Myeloma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Angelman syndrome<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Angelman Syndrome Current Treatment Landscape<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Angelman syndrome epidemiology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Angelman syndrome market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Angelman syndrome pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Atopic dermatitis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Atopic dermatitis Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Atopic dermatitis Treatment Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Atopic Dermatitis Upcoming Therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">metastatic non-small cell lung cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Multiple Myeloma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Multiple MYELOMA drugs Market.<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Multiple Myeloma Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Myelodysplastic Syndrome Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Myelodysplastic Syndrome Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Myelodysplastic Syndrome Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Myelodysplastic Syndromes<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Non-small cell lung cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Non-Small Cell Lung Cancer (NSCLC)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Non-Small Cell Lung Cancer Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Osteoporosis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Osteoporosis drugs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Osteoporosis market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Osteoporosis therapy Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Osteoporosis treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Advanced Multiple Myeloma<\/span>","<span class=\"advgb-post-tax-term\">Angelman syndrome<\/span>","<span class=\"advgb-post-tax-term\">Angelman Syndrome Current Treatment Landscape<\/span>","<span class=\"advgb-post-tax-term\">Angelman syndrome epidemiology<\/span>","<span class=\"advgb-post-tax-term\">Angelman syndrome market<\/span>","<span class=\"advgb-post-tax-term\">Angelman syndrome pipeline<\/span>","<span class=\"advgb-post-tax-term\">Atopic dermatitis<\/span>","<span class=\"advgb-post-tax-term\">Atopic dermatitis Market<\/span>","<span class=\"advgb-post-tax-term\">Atopic dermatitis Treatment Market<\/span>","<span class=\"advgb-post-tax-term\">Atopic Dermatitis Upcoming Therapies<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">metastatic non-small cell lung cancer<\/span>","<span class=\"advgb-post-tax-term\">Multiple Myeloma<\/span>","<span class=\"advgb-post-tax-term\">Multiple MYELOMA drugs Market.<\/span>","<span class=\"advgb-post-tax-term\">Multiple Myeloma Market<\/span>","<span class=\"advgb-post-tax-term\">Myelodysplastic Syndrome Market<\/span>","<span class=\"advgb-post-tax-term\">Myelodysplastic Syndrome Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Myelodysplastic Syndrome Treatment<\/span>","<span class=\"advgb-post-tax-term\">Myelodysplastic Syndromes<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">Non-small cell lung cancer<\/span>","<span class=\"advgb-post-tax-term\">Non-Small Cell Lung Cancer (NSCLC)<\/span>","<span class=\"advgb-post-tax-term\">Non-Small Cell Lung Cancer Market<\/span>","<span class=\"advgb-post-tax-term\">Osteoporosis<\/span>","<span class=\"advgb-post-tax-term\">Osteoporosis drugs<\/span>","<span class=\"advgb-post-tax-term\">Osteoporosis market<\/span>","<span class=\"advgb-post-tax-term\">Osteoporosis therapy Market<\/span>","<span class=\"advgb-post-tax-term\">Osteoporosis treatment<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 months ago","modified":"Updated 8 months ago"},"absolute_dates":{"created":"Posted on Sep 23, 2025","modified":"Updated on Sep 23, 2025"},"absolute_dates_time":{"created":"Posted on Sep 23, 2025 5:03 pm","modified":"Updated on Sep 23, 2025 5:06 pm"},"featured_img_caption":"pharma-news-for-merck-incyte-biocon\n","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/33445","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=33445"}],"version-history":[{"count":2,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/33445\/revisions"}],"predecessor-version":[{"id":33449,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/33445\/revisions\/33449"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/33446"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=33445"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=33445"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=33445"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=33445"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=33445"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}